Browsing by Author "Demir, Bilgin"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Article
    Citation - WoS: 2
    Citation - Scopus: 2
    The Efficacy of Hddpiw-Jsb Solution on Docetaxel-Induced Alopecia of Rats
    (Taylor & Francis Ltd, 2024) Demir, Bilgin; Demirci, Buket; Tataroglu, Canten; Barutca, Sabri; Barutca, Duygu
    ObjectiveChemotherapy induced alopecia (CIA) is one of the most common side effects in cancer patients, however; it doesn't have an effective pharmacological treatment yet. In this study we aimed to research the protective effect of newly developed HDDPiW-jSB solution on docetaxel (DTX) -induced rat alopecia model.Material and MethodsDocetaxel (10 mg/kg/week) was administered to the 6-8 months old rats for three weeks. HDDPiW-jSB solution was applied once or twice a week for 4 weeks beginning prior to one week before DTX. Rat hair follicles were evaluated with hematoxylin-eosin and immune-histochemical staining.ResultsIn the first stage of this study, alopecia was successfully developed by DTX (10 mg/kg/three times) application. In the second stage of the study, application of HDDPiW-jSB solution, did not change the study parameters significantly on control group. The solution improved the anagen hair follicle count and Bcl-2 levels in the skin samples of DTX-induced alopecic rat groups, especially when applied twice weekly. Additionally, level of Caspase 3 was decreased. HDDPiW-jSB solution was safe when applied on the skin.ConclusionTopical HDDPiW-jSB solution could be effective and safe for the protection of DTX-induced alopecia in rat models.
  • Thumbnail Image
    Article
    The Value of Inflammatory Prognostic Index in Older Patients With Hormone Receptor Positive Metastatic Breast Cancer
    (2021) Oktay, Esin; Sahin, Mustafa; Erdogan, Atike Pinar; Ozveren, Ahmet; Yilmaz, Senem; Ekinci, Ferhat; Demir, Bilgin
    Objectives: To search the prognostic value of an inflammation based prognostic score in older patients with hormone positive, Her2 negative metastatic breast cancer. Methods: A retrospective study of 82 female patients aged 65 years and older with hormon receptor positive, Her-2 negative metastatic breast cancer diagnosed between 2011 and 2018 was conducted with collection of clinical and laboratory data. The inflammatory prognostic index (IPI) was calculated as C-reactive protein × NLR (neutrophil/ lym- phocyte ratio)/serum albumin. Survival estimates were calculated with Kaplan-Meier method. Results: The optimal cut-off points of IPI for the stratification of OS was found to be 0,75. Based on this cutoff value, patients were categorized as IPI-high and IPI-low group. High IPI was significantly associated with advanced stage at diagnosis. (p=0.03) The mean OS was 64 months in the IPI-high group and 66.9 months in the IPI-low group. (p=0,813) In patients receiving hormonotherapy in first line treatment PFS was 34.6 months in the IPI-low group and 14.5 months in the IPI high group, and a statistically significant difference was found compared to patients who received chemo- therapy in the first line. (p=0,042). Conclusion: Measurement of systemic inflammatory response in older adults with metastatic breast cancer is reliable, available, and can be clinically incorporated into current geriatric oncology algorithms